1.
Schooley RT, Hirsch MS, Colvin R.B, Cosimi AB, Tolkoff-Rubin NE, McCluskey RT, Burton RC, Russell PS, Herrin JT, Delmonico FL, Giorgi JV, Henle W and Rubin RH. Association of herpes virus infections with T-lymphocyte subset alterations, glomerulopathy, and opportunistic infections following renal transplantation.
N Engl J Med.
1983; 308:307-13.
2. Blumberg RS, Paradis TJ, Hartshorn KL, Vogt M, Ho DD, Hirsch MS, Leban J, Sato VL and Schooley RT. Antibody-dependent cell-mediated cytotoxicity (ADCC) against cells infected with the Human Immunodeficiency Virus. J Infect Dis. 1987; 156:878-84.
3. Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan JC, Hirsch MS and Schooley RT. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987; 328:345-8.
4. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A, Young R, Moss B and Schooley RT. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with HIV-1. Proc Natl Acad Sci, USA. 1989; 86:9514-8.
5. Fischl MA, Richman DD, Grieco M, Gottlieb MS, Volberding P, Laskin D, Leedom JM, Schooley RT, Grooprnan J, Mildvan D, Jackson GG, Durack D, King D and the AZT Collaborative Working Group. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl J Med. 1987; 317:185-91.
6. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E. A Phase I/II escalating dose trial of recombinant soluble CD4 therapy in patients with AIDS or AIDS Related Complex. Ann Intern Med. 1990; 112:247-253.
7. Wyles DL, Kaihara KA and Schooley RT. Synergy of an HCV NS4A Antagonist in Combination with HCV protease and polymerase inhibitors. Antimicrobial Agents Chemother, 2008; 52:1862-4
8. Schooley RT. Spino C. Kuritzkes D. Walker BD. Valentine FA. Hirsch MS. Cooney E. Friedland G. Kundu S. Merigan TC Jr. McElrath MJ. Collier A. Plaeger S. Mitsuyasu R. Kahn J. Haslett P. Uherova P. deGruttola V. Chiu S. Zhang B. Jones G. Bell D. Ketter N. Twadell T. Chernoff D. Rosandich M. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis. 2000; 182:1357-64.
9. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E and Cheng AK for the Study 902 Team. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002; 16:1257-63.
10. Frey G, Rits-Volloch S, Zhang X-Q , Schooley RT, Chen B, Harrison SC. Small molecules that bind the inner core of gp41. Proc Nat Acad Sci USA 2006;103:13938-43.
11. Wyles DW, Kaihara KA, Vaida F and Schooley RT. Synergy of small molecular inhibitors of HCV replication directed at multiple viral targets. J Virol. 2007; 81:3005-8.
12. Grünberger C, Wyles DL, Kaihara KA, and Schooley RT. Three-Drug synergistic interactions of small molecular inhibitors of Hepatitis C virus (HCV) replication. J Infect Dis 2008. 197: 42-5.
13. Schooley RT and Mellors JW. No Cure Yet for HIV-1 But Therapeutic Research Presses On. J Infect Dis. In Press, 2007.
14. Smith DM and Schooley RT. Running with Scissors: Using Antiretroviral Therapy without Monitoring Viral Load. Clin Infect Dis. 2008; 46: 1598-1600.
Click here to view Dr. Schooley's CV